Table 3. Long-term clinical outcome.

	Octogenarians, n = 261 446 patient-years			Non-octogenarians, n = 483 1056 patient-years		P-value
Data provided as n (%) or mean ± SD. ASA: acetylsalicylic acid; NOACs: non-vitamin K dependent oral anticoagulants; TIA: transient ischemic attack.
Age at follow-up, yrs	86.1 ± 3.3			73.2 ± 7.6		< 0.0001
Time from study inclusion to follow-up in years	1.7 ± 1.3			2.3 ± 1.6		< 0.0001
	Events/Patient-years	Observed rate		Events/Patient-years	Observed rate
Primary efficacy endpoint	61/446	13.7 (10.8-17.12)		80/1,056	7.6 (6.1-9.3)	< 0.0001
Primary safety endpoint	30/446	6.7 (4.8-9.4)		47/1,056	4.4 (3.4-5.9)	0.48
Combined hazard endpoint	82/446	18.4 (15.1-22.2)		116/1,056	11.0 (9.2-13.0)	< 0.0001
All-cause death	83/446	18.6 (15.3-22.5)		101/1,056	9.6 (7.9-11.5)	< 0.0001
Cardiovascular/unexplained death	58/446	13.0 (10.2-16.4)		70/1,056	6.6 (5.3-8.3)	< 0.0001
Stroke and TIA (any)	19/446	4.3 (2.7-6.6)		22/1,056	2.1 (1.4-3.1)	0.01
Stroke without TIA (any)	15/446	3.4 (2.0-5.5)		20/1,056	1.9 (1.2-2.9)	0.049
Disabling stroke	9/446	2.0 (1.1-3.8)		12/1,056	1.1 (0.7-2.0)	< 0.0001
Non-disabling stroke	7/446	1.6 (0.8-3.2)		7/1,056	0.7 (0.3-1.4)	< 0.0001
Ischemic stroke	15/446	3.3 (2.0-5.5)		18/1,056	1.7 (1.1-2.7)	< 0.0001
Hemorrhagic stroke	0/446	0		2/1,056	0.2 (0.1-0.7	0.005
TIA	4/446	0.9 (0.3-2.3)		2/1,056	0.2 (0.1-0.7)	0.02
Systemic embolism	1/446	0.2 (0.3-2.3)		3/1,056	0.3 (0.1-0.8)	0.35
Any bleeding	40/446	9.0 (6.7-12.0)		58/1,056	5.5 (4.3-7.0)	0.020
Major bleedings	21/446	4.7 (3.1-7.1)		26/1,056	2.5 (1.7-3.6)	0.025
Anti-thrombotic therapy at time of follow-up
Any oral anticoagulation	25 (7.3%)			42 (8.7%)		0.77
Vitamin K antagonists	5 (1.9%)			17 (3.5%)		0.20
NOACs	18 (6.9%)			23 (4.8%)		0.26
ASA	172 (65.9%)			310 (64.2%)		1.0
Platelet inhibitors other than ASA	40 (15.3%)			63 (13.0%)		0.90